Welcome to our dedicated page for Immunitybio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImmunityBio, Inc. (NASDAQ: IBRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including annual reports, quarterly reports, and current reports on Form 8‑K. As a commercial-stage biotechnology issuer focused on IL‑15–based immunotherapies and cell therapies, ImmunityBio uses these filings to report financial performance, capital structure changes, governance matters, and material agreements related to its ANKTIVA‑centered portfolio.
Annual reports (Form 10‑K) and quarterly reports (Form 10‑Q) detail product revenue from ANKTIVA, research and development spending on programs such as QUILT‑3.032 in non‑muscle invasive bladder cancer and QUILT‑2.023/3.055 in non‑small cell lung cancer, and broader risk factors associated with developing and commercializing biologic therapies. These filings also summarize segment information, which the company describes as including the United States and Europe, and discuss liquidity, debt obligations, and equity plans.
Current reports (Form 8‑K) capture specific material events. Recent 8‑Ks disclose an at‑the‑market offering program amendment authorizing additional common stock sales under a shelf registration statement, a registered direct offering of common shares and warrants, adoption of the 2025 Equity Incentive Plan, and the appointment of independent directors. Other 8‑Ks reference earnings press releases that report net product revenue growth for ANKTIVA and changes in cash, cash equivalents, and marketable securities.
Investors interested in capital markets activity can review filings describing increases in authorized common stock, revenue interest liabilities, and equity incentive structures. Governance‑focused readers can examine disclosures on board composition, director compensation policies, and the preliminary approval of a settlement of stockholder derivative actions that includes corporate governance reforms.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language. Instead of parsing lengthy 10‑K or 10‑Q documents line by line, users can see concise overviews of ImmunityBio’s revenue trends, R&D priorities, financing arrangements, and risk disclosures, then drill down into the original SEC documents when more detail is needed.
For those tracking IBRX insider and executive activity, forms such as Form 4 and proxy‑related materials (when available) provide insight into equity awards, option grants, and ownership changes, complementing the broader financial and operational picture presented in periodic reports.
ImmunityBio, Inc. disclosed that one of its directors filed an initial insider ownership statement effective 12/12/2025, reporting no beneficial ownership of ImmunityBio securities.
The filing shows the director does not hold any shares or derivative securities of the company, was filed by a single reporting person, and was signed by /s/ Philip LoScalzo as attorney-in-fact.
ImmunityBio, Inc. appointed Bruce Wendel to its board of directors, effective December 12, 2025, with his term running until the 2026 annual meeting of stockholders. The board determined that he qualifies as an independent director under Nasdaq and SEC rules.
Wendel brings extensive pharmaceutical and biotech experience, including senior roles at ProMetic Biosciences, Hepalink USA, Scientific Protein Laboratories, Abraxis BioScience, Bristol-Myers Squibb, IVAX, and American Pharmaceutical Partners, as well as prior public company board service at GT BioPharma and Verastem.
As a non-employee director, he will receive $50,000 in annual cash compensation and an initial stock option grant under ImmunityBio’s 2025 Equity Incentive Plan with a Black-Scholes value of $300,000, vesting over three years and fully vesting immediately before a Change in Control, along with reimbursement of reasonable travel expenses.
ImmunityBio (IBRX) filed its Q3 2025 report showing rapid revenue ramp but continued losses and liquidity pressure. Total revenue reached $32.1 million for the quarter, up from $6.1 million a year ago, driven by U.S. commercialization of ANKTIVA. For the nine months, revenue was $75.0 million versus $7.2 million in 2024.
The company reported a Q3 net loss of $67.3 million and a loss from operations of $55.6 million. Year-to-date operating cash outflows were $234.6 million. Cash and cash equivalents were $60.2 million and marketable securities were $197.6 million as of September 30, 2025. Accounts receivable increased to $32.0 million, reflecting growing product sales.
Total liabilities were $1.04 billion, including a related-party convertible note at fair value of $500.8 million, a revenue interest liability of $316.1 million, and warrant liabilities of $115.2 million. The company raised $346.8 million net through equity offerings year-to-date, including “at-the-market” sales and other equity issuances. Shares outstanding were 984,965,179 as of October 30, 2025.
Management disclosed substantial doubt about continuing as a going concern without additional funding, noting reliance on existing cash, product sales, future equity offerings, and potential affiliated loans. In July 2025, ANKTIVA received UK marketing authorization, the first approval outside the U.S.
ImmunityBio, Inc. furnished a press release announcing its financial results for the third quarter and nine months ended September 30, 2025, and its financial position as of September 30, 2025.
The press release, dated November 4, 2025, is included as Exhibit 99.1 to this Form 8-K. The information under Item 2.02 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act.
ImmunityBio (IBRX) increased its authorized common stock to 1,650,000,000 shares from 1,350,000,000 through a stockholder written consent, approved by holders of 649,794,019 shares (approximately 66.0% of voting power). The amendment was recommended by the Board and will become effective no earlier than twenty calendar days after mailing; the company anticipates an effective date on or about November 10, 2025.
The company states the higher authorization is intended to cover current committed issuances and expected funding needs, including potential equity raises or convertible instruments that require reserved shares. As context, 984,965,179 shares were outstanding as of October 7, 2025. The filing notes that issuing additional shares could dilute existing stockholders and may affect the share price.
No appraisal or dissenters’ rights apply, and no further stockholder vote is required.
ImmunityBio, Inc. stockholders holding 649,794,019 shares, representing approximately 66.0% of voting power as of October 7, 2025, delivered a written consent approving a Certificate of Amendment to increase authorized common stock. The company reported 984,965,179 shares outstanding as of the Record Date and expects the Certificate of Amendment to become effective no earlier than twenty calendar days after mailing, with an anticipated effective date on or about November, 2025. The amendment restates authorized shares to 1,670,000,000 total shares, of which 1,650,000,000 are Common Stock and 20,000,000 are Preferred Stock. The disclosure notes that no appraisal rights exist under Delaware law for this action and that the Board used majority written consent to avoid a special meeting.
ImmunityBio reported a federal court's preliminary approval of a proposed settlement to resolve several stockholder derivative lawsuits brought nominally on behalf of the company. Under the Stipulation, the company will adopt specified corporate governance reforms and will pay attorneys' fees in exchange for a full and complete release and dismissal of the derivative claims. The company states it expects those attorneys' fees will be funded by its insurance carrier. The court has set a final approval hearing for November 4, 2025. The company has posted the Notice and the Stipulation to its Investor Relations website and attached them as Exhibits 99.1 and 99.2.
ImmunityBio, Inc. (IBRX) 10-Q — Quarter ended June 30, 2025: Condensed consolidated assets totaled $402,076 as of June 30, 2025, including $137,658 cash and cash equivalents, $16,000 marketable securities and $22,126 accounts receivable. Total current assets were $208,132. Major non‑current assets include PP&E net $133,004 and goodwill/intangibles net $14,977. Total liabilities were $971,895, driven notably by a $492,084 related‑party convertible note payable and a $307,049 revenue interest liability; warrant liabilities were $66,957. Stockholders' deficit was $(570,749).
Operating results and cash flows: Product revenue increased to $26,421 for Q2 2025 (Q2 2024: $990) and $42,930 for six months 2025 (six months 2024: $990). Loss from operations was $(71,285) for Q2 and $(135,714) for six months; net loss was $(92,574) for Q2 and $(222,240) for six months. Net cash used in operating activities for the six months was $(165,651). The company discloses an accumulated deficit of $3.6 billion and states substantial doubt about going concern without additional funding, though management cites expected support from the Founder and other sources.
ImmunityBio (IBRX) filed an 8-K disclosing a capital raise. On 24 Jul 2025 the company executed a Securities Purchase Agreement to sell 29,629,632 common shares together with five-year warrants for an equal number of shares. Each share-and-warrant unit is priced at $2.70, while the warrants carry a $3.24 exercise price and become immediately exercisable. Gross proceeds are expected to be about $80 million before fees and expenses; closing is targeted for 28 Jul 2025 subject to customary conditions.
Piper Sandler & Co. will act as exclusive placement agent under a separate agreement and will receive a cash fee equal to 6.0 % of gross proceeds (no fee on warrant exercises). The securities are being issued from the company’s effective shelf registration statement on Form S-3ASR.
The 8-K also references two press releases dated 25 Jul 2025: (i) a business update with preliminary, unaudited Q2 results and regulatory developments, and (ii) an announcement of the registered direct offering. Full financial figures were not included in the filing; exhibits provide the SPA, warrant form, placement agency agreement, legal opinion and related consents.